Standard Biotools (LAB) Cash from Investing Activities (2010 - 2026)

Standard Biotools (LAB) has reported Cash from Investing Activities for 17 consecutive years, with $191.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 1206.6% year-over-year to $191.1 million; the TTM figure through Mar 2026 stood at $203.9 million (up 241.36% YoY), while the FY2025 annual figure was $27.4 million, down 92.45% from the prior year.
• Cash from Investing Activities climbed to $191.1 million in Q1 2026 per LAB's latest filing, from -$8.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $318.1 million in Q1 2024 and bottomed at -$138.2 million in Q2 2022.
• Historically, Cash from Investing Activities has averaged $30.2 million across 5 years, with a median of $14.6 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 1419.96% — and 2023, when it surged 5071.66%.
• Standard Biotools' Cash from Investing Activities stood at $40.2 million in 2022, then sank by 132.59% to -$13.1 million in 2023, then jumped by 296.13% to $25.7 million in 2024, then slumped by 131.25% to -$8.0 million in 2025, then surged by 2476.74% to $191.1 million in 2026.
• Business Quant data shows LAB's Cash from Investing Activities at $191.1 million in Q1 2026, -$8.0 million in Q4 2025, and -$6.7 million in Q3 2025.